News
-
Powder characterization specialist Freeman Technology is offering a free 35-page downloadable booklet titled “An Introduction to Powders” that includes information particularly useful for development and optimization of dry powder inhalers, the company says. Authored by… Read more . . .
-
The US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended that children aged 2-8 should get a nasal spray flu vaccine if available instead of an injection. The… Read more . . .
-
Device component company Presspart Manufacturing has announced that former Lupin pulmonary research scientist Abhay Singh and former Sanofi QC readiness analyst Jacqueline Green have joined Presspart’s Inhalation Product Technology Centre (IPTC) team. Singh has been… Read more . . .
-
According to Aradigm, the first patient in the Phase 3 ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial of Pulmaquin inhaled ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis has been dosed. The other Phase 3… Read more . . .
-
Verona Pharma has announced that it will stop development of its VRP700 inhaled antitussive after the drug failed to produce statistically significant reduction in cough frequency compared to placebo in a Phase 2a clinical trial.… Read more . . .
-
Under the terms of a newly reached settlement, Perrigo and Catalent will be able to market limited quantities of their generic version of Teva’s Proair HFA albuterol MDI starting in December 2016. Beginning in July… Read more . . .
-
Asmacure has announced that a Phase 1/2a trial of ASM-024 inhalation powder found that the drug was safe and well tolerated. In April 2013, the company announced that it had dosed the first patient in… Read more . . .
-
According to Consort Medical’s financial report for the fiscal year ending April 2014, its Bespak subsidiary is adding a 4,200 sq m facility for the manufacture of a nicotine DPI and a 5,200 sq m… Read more . . .
-
Discovery Laboratories says that it will use the $1.9 million it has received from the National Heart, Lung, and Blood Institute (NHLBI) for a Phase 2a trial of Aerosurf inhaled KL4 surfactant that is already… Read more . . .
-
GlaxoSmithKline and Theravance have announced that two Phase 3 studies have shown that COPD patients using the Incruse Ellipta umeclidinium (UMEC) DPI in conjunction with the Breo/Relvar Ellipta fluticasone furoate/vilanterol (FF/VI) DPI achieved a statistically… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany